Condition

HIV-infection/AIDS

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting0

Common interventions8

Lead sponsors shown5

Clinical trials

5 shown

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)NCT04373551 · 2022-03-07

COMPLETED

Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 InfectionNCT03403569 · 2018-09-01

COMPLETED

Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV InfectionNCT03147859 · 2017-11-01

UNKNOWN

Adherence Connection for Counseling, Education, and SupportNCT02753049 · 2016-11-23

UNKNOWN

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of MidazolamNCT01827540 · 2013-03-01

COMPLETED

Common interventions

CenicrivirocDRUG1 Cultural adaptation of a patient-provider communication toolBEHAVIORAL1 DolutegravirDRUG1 MidazolamDRUG1 Peer led mHelath behavioral interventionBEHAVIORAL1 Placebo Oral TabletDRUG1 Triptolide WilfordiiDRUG1 Vedolizumab (brand name Entyvio)BIOLOGICAL1

Leading sponsors

New York University 1 Ottawa Hospital Research Institute 1 Peking Union Medical College Hospital 1 Tobira Therapeutics, Inc. 1 University of Alabama at Birmingham 1

Trial status mix

COMPLETED3

UNKNOWN2

Phase mix

NA2

PHASE11

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.